4.8 Article

A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 119, 期 1, 页码 91-98

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI37141

关键词

-

资金

  1. Dutch Organization for Scientific Research [916.56.107]
  2. Dutch Cancer Society [2002-2734]
  3. European Community [FIGR-CT-2003-508842]
  4. DNA repair [LSHG-CT-2005-512113]
  5. NIH [5-R37-CA050519-16, PO1-CA92584]
  6. NATIONAL CANCER INSTITUTE [P01CA092584, R37CA050519] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Radiosensitive T-B- severe combined immunodeficiency (RS-SCID) is caused by defects in the nonhomologous end-joining (NHEJ) DNA repair pathway, which results in failure of functional V(D)J recombination. Here we have identified the first human RS-SCID patient to our knowledge with a DNA-PKcs missense mutation (L3062R). The causative mutation did not affect the kinase activity or DNA end-binding capacity of DNA-PKcs itself; rather, the presence of long P-nucleotide stretches in the immunoglobulin coding joints indicated that it caused insufficient Artemis activation, something that is dependent on Artemis interaction with autophosphorylated DNA-PKcs. Moreover, overall end-joining activity was hampered, suggesting that Artemis-independent DNA-PKcs functions were also inhibited. This study demonstrates that the presence of DNA-PKcs kinase activity is not sufficient to rule out a defect in this gene during diagnosis and treatment of RS-SCID patients. Further, the data suggest that residual DNA-PKcs activity is indispensable in humans.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture

Sanjiban Chakrabarty, William F. Quiros-Solano, Maayke M. P. Kuijten, Ben Haspels, Sandeep Mallya, Calvin Shun Yu Lo, Amr Othman, Cinzia Silvestri, Anja van de Stolpe, Nikolas Gaio, Hanny Odijk, Marieke van de Ven, Corrina M. A. de Ridder, Wytske M. van Weerden, Jos Jonkers, Ronald Dekker, Nitika Taneja, Roland Kanaar, Dik C. van Gent

Summary: This study developed a microfluidic platform for evaluating cancer treatment response and predicting drug efficacy in breast and prostate tumors. By culturing tumor slices under controlled growth conditions, the platform allows reliable assessment of chemotherapeutic sensitivity and enables detailed mechanistic studies.

CANCER RESEARCH (2022)

Article Immunology

Age and Primary Vaccination Background Influence the Plasma Cell Response to Pertussis Booster Vaccination

Annieck M. Diks, Pauline Versteegen, Cristina Teodosio, Rick J. Groenland, Bas de Mooij, Anne-Marie Buisman, Alba Torres-Valle, Martin Perez-Andres, Alberto Orfao, Guy A. M. Berbers, Jacques J. M. van Dongen, Magdalena A. Berkowska

Summary: This study used high-dimensional flow cytometry to investigate changes in B cells after administration of an acellular pertussis booster vaccine. The results showed that the expansion and maturation of plasma cells were the most significant cellular changes post-vaccination, and were more pronounced in individuals primed with whole-cell vaccine.

VACCINES (2022)

Article Biochemistry & Molecular Biology

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests

Titia G. Meijer, Luan Nguyen, Arne Van Hoeck, Anieta M. Sieuwerts, Nicole S. Verkaik, Marjolijn M. Ladan, Kirsten Ruigrok-Ritstier, Carolien H. M. van Deurzen, Harmen J. G. van de Werken, Esther H. Lips, Sabine C. Linn, Yasin Memari, Helen Davies, Serena Nik-Zainal, Roland Kanaar, John W. M. Martens, Edwin Cuppen, Agnes Jager, Dik C. van Gent

Summary: Germline BRCA1/2 mutation status predicts response to PARP inhibitors in breast cancer patients. Non-germline BRCA1/2 mutations and HRD tumors may also be sensitive to PARP inhibitors. The RECAP test can identify HRD tumors and correlates partially with DNA-based HRD tests. The test also identifies deficiencies in other DNA repair genes.

ONCOGENE (2022)

Article Multidisciplinary Sciences

Rapid recruitment of p53 to DNA damage sites directs DNA repair choice and integrity

Yu-Hsiu Wang, Teresa L. F. Ho, Anushya Hariharan, Hui Chin Goh, Yao Liang Wong, Nicole S. Verkaik, May Yin Lee, Wai Leong Tam, Dik C. van Gent, Ashok R. Venkitaraman, Michael P. Sheetz, David P. Lane

Summary: This study reveals that p53 rapidly accumulates at DNA damage sites and plays a critical role in directing DNA repair dynamics and integrity.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Medicine, General & Internal

The COMPLETE trial: HolistiC early respOnse assessMent for oroPharyngeaL cancEr paTiEnts; Protocol for an observational study

Gerda M. Verduijn, Marta E. Capala, Nienke D. Sijtsema, Iris Lauwers, Hernandez Juan A. Tamames, Wilma D. Heemsbergen, Aniel Sewnaik, Jose A. Hardillo, Hetty Mast, Yvette van Norden, Maurice P. H. M. Jansen, Aad van der Lugt, Dik C. van Gent, Mischa S. Hoogeman, Bianca Mostert, Steven F. Petit

Summary: This study aims to gain insights into novel potential prognostic biomarkers to predict response to treatment in HPV-negative patients with OPSCC.

BMJ OPEN (2022)

Article Oncology

Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study

Nienke Brouwer, Sergio Matarraz, Stefan Nierkens, Mattias Hofmans, Michaela Novakova, Elaine Sobral da Costa, Paula Fernandez, Anne E. Bras, Fabiana Vieira de Mello, Ester Mejstrikova, Jan Philippe, Georgiana Emilia Grigore, Carlos E. Pedreira, Jacques J. M. van Dongen, Alberto Orfao, Vincent H. J. van der Velden

Summary: Acute megakaryoblastic leukemia (AMKL) is a rare and heterogeneous subtype of acute myeloid leukemia (AML). Flowcytometric immunophenotyping can accurately diagnose AMKL and multiple subgroups exist within these patients.

CANCERS (2022)

Article Oncology

Functional Ex Vivo Tissue-Based Chemotherapy Sensitivity Testing for Breast Cancer

Marjolijn M. Ladan, Titia G. Meijer, Nicole S. Verkaik, Zofia M. Komar, Carolien H. M. van Deurzen, Michael A. den Bakker, Roland Kanaar, Dik C. van Gent, Agnes Jager

Summary: This study explores the feasibility of a functional sensitivity test for the chemotherapeutic agents cisplatin and docetaxel on breast cancer tissue slices in culture. The results show that these two agents need to be analyzed differently and the test has been adapted for biopsies from metastatic breast tumors. The test is now ready for evaluation of its predictive value in clinical trials.

CANCERS (2022)

Article Oncology

Quality Assessment of a Large Multi-Center Flow Cytometric Dataset of Acute Myeloid Leukemia Patients-A EuroFlow Study

Anne E. Bras, Sergio Matarraz, Stefan Nierkens, Paula Fernandez, Jan Philippe, Carmen-Mariana Aanei, Fabiana Vieira de Mello, Leire Burgos, Alita J. Van der Sluijs-Gelling, Georgiana Emilia Grigore, Jacques J. M. van Dongen, Alberto Orfao, Vincent H. J. van der Velden

Summary: Flow cytometry plays an important role in the diagnosis of acute myeloid leukemia. This study reports on the construction of a large database of acute myeloid leukemia patients and discusses the quality assessment procedure used. The study shows that obtaining reproducible flow cytometric data across centers is feasible with strict quality assessment.

CANCERS (2022)

Article Oncology

Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome

Elen Oliveira, Elaine S. Costa, Juana Ciudad, Giuseppe Gaipa, Lukasz Sedek, Susana Barrena, Tomasz Szczepanski, Chiara Buracchi, Daniela Silvestri, Patricia F. R. Siqueira, Fabiana Mello, Rafael C. Torres, Leonardo M. R. Oliveira, Isabelle V. C. Fay-Neves, Edwin Sonneveld, Vincent H. J. van der Velden, Esther Mejstrikova, Josep-Maria Ribera, Valentino Conter, Martin Schrappe, Jacques J. M. van Dongen, Marcelo G. P. Land, Alberto Orfao

Summary: An imbalanced ratio of endothelial cells (EC) to mesenchymal stem cells (MSC) in the bone marrow at day +78 of therapy is associated with a shorter disease-free survival (DFS) in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients, independent of their measurable residual disease (MRD) status.

CANCERS (2022)

Article Cell Biology

Immune Determinants of Viral Clearance in Hospitalised COVID-19 Patients: Reduced Circulating Naive CD4+T Cell Counts Correspond with Delayed Viral Clearance

Mihaela Zlei, Igor A. Sidorov, Simone A. Joosten, Mirjam H. M. Heemskerk, Sebenzile K. Myeni, Cilia R. Pothast, Caroline S. de Brouwer, A. Linda Boomaars-van der Zanden, Krista E. van Meijgaarden, Shessy T. Morales, Els Wessels, Jacqueline J. Janse, Jelle J. Goeman, Christa M. Cobbaert, Aloys C. M. Kroes, Suzanne C. Cannegieter, Meta Roestenberg, Leonardus G. Visser, Marjolein Kikkert, Mariet C. W. Feltkamp, Sesmu M. Arbous, Frank J. T. Staal, Tom H. M. Ottenhoff, Jacques J. M. van Dongen, Anna H. E. Roukens, Jutte J. C. de Vries

Summary: This study highlights the importance of immune responses in determining disease severity and viral clearance after SARS-CoV-2 infection. Delayed viral clearance is associated with more severe disease, higher levels of neutralising antibodies, and ongoing immune activation. Early viral clearance and less critical illness are correlated with peak neutralising antibodies, higher levels of CD4 T cells, and particularly naive CD4+ T cells, suggesting their role in early control of the virus.
Article Oncology

Ex Vivo Functional Assay for Evaluating Treatment Response in Tumor Tissue of Head and Neck Squamous Cell Carcinoma

Marta E. Capala, Katrin S. Pachler, Iris Lauwers, Maarten A. de Korte, Nicole S. Verkaik, Hetty Mast, Brend P. Jonker, Aniel Sewnaik, Jose A. Hardillo, Stijn Keereweer, Dominiek Monserez, Senada Koljenovic, Bianca Mostert, Gerda M. Verduijn, Steven Petit, Dik C. van Gent

Summary: The study developed an assay to evaluate the response of head and neck tumor cells to radiation and chemotherapy. The results showed that different tumors had a varied reaction to treatment, with sensitive tumors showing partial DNA damage repair, decreased proliferation, and increased cell death, while resistant tumors were able to recover from treatment. The next step is to determine if these differences can predict treatment outcomes in a clinical trial.

CANCERS (2023)

Article Immunology

Single-cell immune profiling reveals thymus-seeding populations, T cell commitment, and multilineage development in the human thymus

Martijn Cordes, Kirsten Cante-Barrett, Erik B. van den Akker, Federico A. Moretti, Szymon M. Kielbasa, Sandra A. Vloemans, Laura Garcia-Perez, Cristina Teodosio, Jacques J. M. van Dongen, Karin Pike-Overzet, Marcel J. T. Reinders, Frank J. T. Staal

Summary: This study used a combination of single-cell techniques and functional assays to analyze the development of T cells in the human thymus. The researchers identified progenitor populations in the thymus that can also be found in the bone marrow. Additionally, they found that the human thymus supports the development of various immune cells, which is important for guiding regenerative therapies.

SCIENCE IMMUNOLOGY (2022)

Article Medicine, Research & Experimental

Distinct early cellular kinetics in participants protected against colonization upon Bordetella pertussis challenge

Annieck M. Diks, Hans de Graaf, Cristina Teodosio, Rick J. Groenland, Bas de Mooij, Muktar Ibrahim, Alison R. Hill, Robert C. Read, Jacques J. M. van Dongen, Magdalena A. Berkowska

Summary: This study used high-dimensional flow cytometry to monitor the cellular responses to Bordetella pertussis challenge in the blood of 15 healthy donors. The results showed that individuals protected against colonization exhibited different early cellular responses compared to colonized individuals. These early cellular immune responses can be further characterized and potentially linked to an efficient mucosal immune response, ultimately evaluating the protective efficacy of new B. pertussis vaccine candidates.

JOURNAL OF CLINICAL INVESTIGATION (2023)

暂无数据